Overview Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer Status: Completed Trial end date: 2013-04-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether OPB-51602 is safe and tolerable when given daily by mouth to subjects with advanced solid tumors. Phase: Phase 1 Details Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.